文献速递类风湿关节炎

类风湿关节炎患者使用JAK抑制剂与阿达木单抗相比的主要不良心血管事件和静脉血栓栓塞事件风险:一项全国性队列研究

Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
PubMed 文献 · Ann Rheum Dis · 2022-10-05

该研究基于法国国家健康数据系统的全国性人群队列,纳入2017年7月1日至2021年5月31日期间首次配发JAK抑制剂(托法替布和巴瑞替尼)或阿达木单抗的类风湿关节炎患者。主要终点为主要不良心血管事件(MACE)和静脉血栓栓塞事件(VTE)。暴露组与非暴露组MACE风险HRw 1.0(95%CI 0.7至1.5)(p=0.99),VTE风险HRw 1.1(95%CI 0.7至1.6)(p=0.63),均无显著差异。

要点

  • 在类风湿关节炎患者中,启动JAK抑制剂与阿达木单抗相比,MACE和VTE风险均无显著差异。
  • 研究结果在65岁及以上且至少有一个心血管危险因素的患者中保持一致,但研究把握度不足。
  • 该研究为JAK抑制剂的心血管和静脉血栓栓塞安全性提供了令人安心的数据。

核心结论

  • 该研究提供了令人安心的数据,表明类风湿关节炎患者启动JAK抑制剂与阿达木单抗相比,MACE和VTE风险无显著差异,包括心血管疾病高危患者。

研究设计与样本

  • 法国国家健康数据系统的全国性人群队列研究,暴露组为启动JAK抑制剂(托法替布和巴瑞替尼)的患者,非暴露组为启动阿达木单抗的患者。
  • 纳入2017年7月1日至2021年5月31日期间首次配发JAK抑制剂或阿达木单抗且患有类风湿关节炎的所有个体。
  • 采用逆概率治疗加权法估计加权风险比(HRw),以校正混杂因素,并将甲氨蝶呤合并用药作为时变变量。

主要发现

  • 队列共纳入15835例患者:暴露组8481例,非暴露组7354例;平均年龄分别为59.3岁和55.3岁,女性分别占78.3%和71.2%。
  • 随访期间,暴露组和非暴露组分别发生54例和35例MACE,以及75例和32例VTE。
  • 暴露组与非暴露组相比,MACE风险无显著差异:HRw 1.0(95%CI 0.7至1.5)(p=0.99)。
  • 暴露组与非暴露组相比,VTE风险无显著差异:HRw 1.1(95%CI 0.7至1.6)(p=0.63)。
  • 尽管把握度不足,结果在65岁及以上且至少有一个心血管危险因素的患者中保持一致。

关键数值与推荐

  • 主要终点为MACE或VTE的发生。
  • 暴露组与非暴露组相比,MACE风险HRw 1.0(95%CI 0.7至1.5)(p=0.99),未达统计学显著。
  • 暴露组与非暴露组相比,VTE风险HRw 1.1(95%CI 0.7至1.6)(p=0.63),未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出尽管把握度不足,结果在65岁及以上且至少有一个心血管危险因素的患者中保持一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib and baricitinib) versus adalimumab in a large real-world population of patients with rheumatoid arthritis. METHODS: We conducted a nationwide population-based cohort study of the French national health data system, the exposed group initiating a JAKi and non-exposed group initiating adalimumab. We included all individuals who had their first dispensation of a JAKi or adalimumab between 1 July 2017 and 31 May 2021 and had rheumatoid arthritis. The primary endpoints were the occurrence of a MACE or VTE. Weighted hazard ratio (HRw) values were estimated with the inverse probability of treatment weighting method to account for confounding factors with concomitant administration of methotrexate as a time-varying variable. RESULTS: The cohort included 15 835 patients: 8481 and 7354 in the exposed and non-exposed groups (mean age 59.3 and 55.3 years, female 78.3% and 71.2%, respectively). During follow-up, 54 and 35 MACEs and 75 and 32 VTEs occurred in the exposed and non-exposed groups, respectively. Risk of MACEs for the exposed versus non-exposed group was not significant: HRw 1.0 (95% CI 0.7 to 1.5) (p=0.99), nor was risk of VTEs significant: HRw 1.1 (0.7 to 1.6) (p=0.63). Despite a lack of power, results were consistent among patients aged 65 years or older with at least one cardiovascular risk factor. CONCLUSIONS: This study provides reassuring data regarding the risks of MACEs and VTEs in patients initiating a JAKi versus adalimumab, including patients at high risk of cardiovascular diseases.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Hoisnard L, Pina Vegas L, Dray-Spira R, et al. Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2022. PMID: 36198438. doi:10.1136/ard-2022-222824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。